---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021888"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:54:37.283218+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q3 net loss widens to $12.5M; CFO van den Boom to step down, Fuhrman appointed

## Summary
- Net loss of $12.5M in Q3 2022 vs $6.6M a year ago; cash and equivalents $263.2M.
- R&D expenses $10.9M (up from $5.5M); G&A expenses $2.7M (up from $1.2M).
- CFO Esther van den Boom resigns effective Dec 31, 2022; will provide transitional consulting services.
- Alan Fuhrman appointed CFO effective Jan 1, 2023; base salary $440k, target bonus 40%, equity grants.
- SURF301 study ongoing; IND for TYRA-200 expected by year-end 2022.

## SEC filing metadata
- accession: 0000950170-22-021888
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/0000950170-22-021888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/tyra-20221028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021888
- JSON: https://secwatch.observer/filing/0000950170-22-021888.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021888.txt

## Key facts
- Earnings Releases
  Tyra Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income Third quarter 2022 net loss was $12.5 million.
  - Period: the quarter ended September 30, 2022
  - Net income: Third quarter 2022 net loss was $12.5 million
  - Result: reported results
  source text: On November 3, 2022, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/0000950170-22-021888-index.htm
- Executive change
  Esther van den Boom departed as Chief Financial Officer at Tyra Biosciences, Inc..
  - Action: resign
  - Role: Chief Financial Officer
  source text: On October 28, 2022, Esther van den Boom, the Chief Financial Officer of Tyra Biosciences, Inc. (the “Company”), informed the Company of her intent to resign as the Company’s Chief Financial Officer, effective December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/0000950170-22-021888-index.htm
- Executive change
  Alan Fuhrman was appointed as Chief Financial Officer at Tyra Biosciences, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On November 1, 2022, the Board of Directors of the Company (the “Board”) appointed Alan Fuhrman to replace Ms. van den Boom as the Company’s Chief Financial Officer, effective January 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000095017022021888/0000950170-22-021888-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.